Case Study

Critical Milestones Achieved Ahead Of Schedule In Lung Cancer Study

CL_Critical Milestones-Lung Cancer Case Study

IQVIA™ Biotech was selected by a biotechnology company preparing to launch an international Phase III clinical trial for its investigational anaplastic lymphoma kinase (ALK) inhibitor in patients with non-small cell lung cancer (NSCLC). As this was a highly competitive space with more than five companies pursuing the same market, the sponsor’s clinical operations team was seeking an oncology-focused partner who could support protocol design and accelerate the start-up process to meet enrollment milestones quickly. IQVIA Biotech’s oncology team leveraged our extensive NSCLC operational experience, global footprint, and strategic resources to execute this large Phase III study.

Following a competitive review, the sponsor selected IQVIA Biotech to lead the study, managing Europe and Asia, while the sponsor managed North America (NA) in-house. This case study will focus on the ex-NA portion of the clinical trial covering more than 100 sites across nearly 20 countries.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of ECM Connection? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: